A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2018-01-11
Target enrollment:
Participant gender:
Summary
This open-label, multicenter, Phase I, dose-escalation study will evaluate the safety,
tolerability, and pharmacokinetics (PK) of GDC-0575 administered alone or in combination with
gemcitabine in participants with refractory solid tumors or lymphoma. In Stage 1, cohorts of
participants will receive multiple ascending oral doses of GDC-0575 alone or in combination
with intravenous gemcitabine. In Stage 2, participants will receive GDC-0575 orally in
combination with intravenous gemcitabine at or below the maximum tolerated dose determined in
Stage 1. Anticipated time on study treatment is until disease progression or unacceptable
toxicity occurs, up to approximately 5 years.